Get the Stockscreener App
93.33
1.06%
-0.9619
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $93.33, with a volume of 890.65K.
It is down -1.06% in the last 24 hours and down -11.67% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$94.29
Open:
$101.23
24h Volume:
890.65K
Relative Volume:
0.80
Market Cap:
$10.79B
Revenue:
$2.72B
Net Income/Loss:
$254.30M
P/E Ratio:
45.16
EPS:
2.0665
Net Cash Flow:
$564.37M
1W Performance:
+3.92%
1M Performance:
-11.67%
6M Performance:
-20.60%
1Y Performance:
-8.10%
1-Day Range:
$92.91
$101.23
1-Week Range:
$90.74
$101.23
52-Week Range:
$88.53
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
93.50 | 10.79B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
421.04 | 159.25B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
195.09 | 132.37B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
431.02 | 32.95B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
105.92 | 28.58B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
149.14 | 24.90B | 15.41B | 1.37B | 2.11B | 7.50 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - marketscreener.com
Evercore ISI Adjusts Price Target on Revvity to $116 From $125 - marketscreener.com
Biotech Firm Revvity Reports Better-Than-Expected Earnings - Investopedia
Revvity's Steady Demand Lifts Q1 Results Above Expectations - Finimize
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
Revvity (RVTY) Surpasses Q1 Estimates and Updates 2025 Outlook - GuruFocus
Revvity: Q1 Earnings Snapshot - Greenwich Time
Revvity, Inc. (RVTY) Implements Majority Voting Standard Followi - GuruFocus
Revvity beats quarterly estimates on steady demand for medical equipment - Reuters
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Revvity Announces Financial Results for the First Quarter of 202 - GuruFocus
Revvity beats Q1 estimates, shares jump 4% By Investing.com - Investing.com Nigeria
Revvity (RVTY) Exceeds Q1 Revenue Expectations with Strong Perfo - GuruFocus
REVVITY Earnings Results: $RVTY Reports Quarterly Earnings - Nasdaq
Revvity beats Q1 estimates, shares jump 4% - Investing.com Australia
(RVTY) Revvity Expects Full-Year 2025 Revenue Range $2.83B$2.87B, vs. FactSet Est of $2.83B - marketscreener.com
Revvity Announces Financial Results for the First Quarter of 2025 - Business Wire
Revvity (RVTY) Q1 Earnings Report Preview: What To Look For - The Globe and Mail
Revvity’s Quarterly Earnings Preview: What You Need to Know - MSN
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely? - MSN
Why Revvity (RVTY) Could Beat Earnings Estimates Again - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Calculating The Fair Value Of Revvity, Inc. (NYSE:RVTY) - simplywall.st
Earnings Preview For Revvity - Benzinga
Revvity Keeps Quarterly Dividend at $0.07 a Share, Payable August 8 to Holders of Record July 18 - marketscreener.com
Lobbying Update: $30,000 of REVVITY INC. lobbying was just disclosed - Nasdaq
Revvity Board Declares Quarterly Dividend - Business Wire
Revvity Board Declares Quarterly Dividend | RVTY Stock News - GuruFocus
Revvity Continues Steady Dividend Program: $0.07 Per Share Coming This August - Stock Titan
Revvity to Unveil VivoJect Image-guided Injection System at AACR - Genetic Engineering and Biotechnology News
Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation - Genetic Engineering and Biotechnology News
Revvity’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | R - GuruFocus
Revvity Fuels the Future of Cancer Science with New Research Solutions - Business Wire
Assessing Revvity: Insights From 6 Financial Analysts - Benzinga
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Crain's Chicago Business
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Choosing a flexible digital platform for drug discovery - Scientific Computing World
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):